Trials / Available
AvailableNCT04457687
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- —
Summary
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lorcaserin | Lorcaserin 10 milligram (mg) tablets orally. |
Timeline
- First posted
- 2020-07-07
- Last updated
- 2025-01-30
Locations
22 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT04457687. Inclusion in this directory is not an endorsement.